PMID- 30167013
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20230928
IS  - 1880-4276 (Print)
IS  - 1883-2148 (Electronic)
IS  - 1880-4276 (Linking)
VI  - 34
IP  - 4
DP  - 2018 Aug
TI  - XANAP: A real-world, prospective, observational study of patients treated with 
      rivaroxaban for stroke prevention in atrial fibrillation in Asia.
PG  - 418-427
LID - 10.1002/joa3.12073 [doi]
AB  - BACKGROUND: ROCKET AF and its East Asian subanalysis demonstrated that 
      rivaroxaban was non-inferior to warfarin for stroke/systemic embolism (SE) 
      prevention in patients with non-valvular atrial fibrillation (NVAF), with a 
      favorable benefit-risk profile. XANAP investigated the safety and effectiveness 
      of rivaroxaban in routine care in Asia-Pacific. METHODS: XANAP was a prospective, 
      real-world, observational study in patients with NVAF newly starting rivaroxaban. 
      Patients were followed at ~3-month intervals for 1 year, or for >/=30 days after 
      permanent discontinuation. Primary outcomes were major bleeding events, adverse 
      events (AEs), serious AEs and all-cause mortality; secondary outcomes included 
      stroke/SE. Major outcomes were adjudicated centrally. RESULTS: XANAP enrolled 
      2273 patients from 10 countries: mean age was 70.5 years and 58.1% were male. 
      49.8% of patients received rivaroxaban 20 mg once daily (od), 43.8% 15 mg od and 
      5.9% 10 mg od. Mean treatment duration was 296 days, and 72.8% of patients had 
      received prior anticoagulation therapy. Co-morbidities included heart failure 
      (20.1%), hypertension (73.6%), diabetes mellitus (26.6%), prior 
      stroke/non-central nervous system SE/transient ischemic attack (32.8%) and 
      myocardial infarction (3.8%). Mean CHADS(2), CHA(2)DS(2)-VASc and HAS-BLED scores 
      were 2.3, 3.7 and 2.1, respectively. The rates (events/100 patient-years [95% 
      confidence interval]) of treatment-emergent major bleeding, stroke and all-cause 
      mortality were 1.5 (1.0-2.1), 1.7 (1.2-2.5) and 2.0 (1.4-2.7), respectively. 
      Persistence was 66.2% at the study end. CONCLUSIONS: The real-world XANAP study 
      demonstrated low rates of stroke and bleeding in rivaroxaban-treated patients 
      with NVAF from Asia-Pacific. The results were consistent with the real-world 
      XANTUS study and ROCKET AF.
FAU - Kim, Young-Hoon
AU  - Kim YH
AD  - Korea University Medical Centre Seoul South Korea.
FAU - Shim, Jaemin
AU  - Shim J
AD  - Korea University Medical Centre Seoul South Korea.
FAU - Tsai, Chia-Ti
AU  - Tsai CT
AD  - National Taiwan University Hospital Taipei Taiwan.
FAU - Wang, Chun-Chieh
AU  - Wang CC
AD  - Chang Gung Memorial Hospital Chang Gung University Taoyuan Taiwan.
FAU - Vilela, Gilbert
AU  - Vilela G
AD  - Philippine Heart Center Quezon City Philippines.
FAU - Muengtaweepongsa, Sombat
AU  - Muengtaweepongsa S
AD  - Faculty of Medicine Stroke Excellence Center Thammasat University Pathum Thani 
      Thailand.
FAU - Kurniawan, Mohammad
AU  - Kurniawan M
AD  - Department of Neurology Faculty of Medicine Cipto Mangunkusumo National Hospital 
      Universitas Indonesia Jakarta Indonesia.
FAU - Maskon, Oteh
AU  - Maskon O
AD  - Department of Medicine National University of Malaysia Medical Centre (UKMMC) 
      Kuala Lumpur Malaysia.
FAU - Li Fern, Hsu
AU  - Li Fern H
AD  - Novena Heart Centre Mount Elizabeth Novena Specialist Centre Singapore City 
      Singapore.
FAU - Nguyen, Thang Huy
AU  - Nguyen TH
AD  - Neurology Department Pham Ngoc Thach Medical University Ho Chi Minh City Vietnam.
FAU - Thanachartwet, Thititat
AU  - Thanachartwet T
AD  - Bayer (South East Asia) Pte Ltd Singapore City Singapore.
FAU - Sim, Kenneth
AU  - Sim K
AD  - Bayer (South East Asia) Pte Ltd Singapore City Singapore.
FAU - Camm, A John
AU  - Camm AJ
AD  - Cardiology Clinical Academic Group St. George's University of London and Imperial 
      College London UK.
CN  - XANAP investigators
LA  - eng
PT  - Journal Article
DEP - 20180706
PL  - Japan
TA  - J Arrhythm
JT  - Journal of arrhythmia
JID - 101263026
PMC - PMC6111488
OTO - NOTNLM
OT  - Asia-Pacific
OT  - bleeding risk
OT  - real world
OT  - rivaroxaban
OT  - stroke prevention
EDAT- 2018/09/01 06:00
MHDA- 2018/09/01 06:01
PMCR- 2018/07/06
CRDT- 2018/09/01 06:00
PHST- 2017/11/20 00:00 [received]
PHST- 2018/04/23 00:00 [accepted]
PHST- 2018/09/01 06:00 [entrez]
PHST- 2018/09/01 06:00 [pubmed]
PHST- 2018/09/01 06:01 [medline]
PHST- 2018/07/06 00:00 [pmc-release]
AID - JOA312073 [pii]
AID - 10.1002/joa3.12073 [doi]
PST - epublish
SO  - J Arrhythm. 2018 Jul 6;34(4):418-427. doi: 10.1002/joa3.12073. eCollection 2018 
      Aug.